Arcutis Biotherapeutics has announced promising Phase 3 trial results for ZORYVE cream, showcasing its efficacy in treating atopic dermatitis, a chronic skin condition. The new data highlights significant improvements in sleep patterns and long-term disease control among patients using this topical treatment. ZORYVE cream appears to reduce the sleep disruptions often associated with atopic dermatitis, offering a substantial quality of life improvement for sufferers. The Phase 3 results underscore the potential of ZORYVE as a breakthrough therapy in managing the persistent symptoms of atopic dermatitis. With its focus on addressing the root inflammatory causes, ZORYVE positions itself as a significant player among dermatological treatments. These findings could pave the way for wider adoption and support among healthcare professionals and patients battling this debilitating skin condition. Arcutis’s commitment to research and innovation in dermatology is evident in these promising outcomes, offering hope for a future with improved management options for atopic dermatitis. This development could also influence the competitive landscape of topical dermatological solutions.
Quiver QuantitativeNew data shows Britain’s night-time economy shrinks by 350 venues in six months
October 19, 2026
New data reveals a significant decline in Britain’s night-time economy, with 350 venues closing within just six months. This downward trend highlights the ongoing challenges